Targeting Mir128-3P Alleviates Myocardial Insulin Resistance and Prevents Ischemia-Induced Heart Failure
Andrea Ruiz-Velasco,Min Zi,Susanne S. Hille,Tayyiba Azam,Namrita Kaur,Juwei Jiang,Binh Nguyen,Karolina Sekeres,Pablo Binder,Lucy Collins,Fay Pu,Han Xiao,Kaomei Guan,Norbert Frey,Elizabeth J. Cartwright,Oliver J. Mueller,Xin Wang,Wei Liu
DOI: https://doi.org/10.7554/elife.54298
IF: 7.7
2020-01-01
eLife
Abstract:Myocardial insulin resistance contributes to heart failure in response to pathological stresses, therefore, a therapeutic strategy to maintain cardiac insulin pathways requires further investigation. We demonstrated that insulin receptor substrate 1 (IRS1) was reduced in failing mouse hearts post-myocardial infarction (MI) and failing human hearts. The mice manifesting severe cardiac dysfunction post-MI displayed elevated mir128-3p in the myocardium. Ischemia-upregulated mir128-3p promoted Irs1 degradation. Using rat cardiomyocytes and human-induced pluripotent stem cell-derived cardiomyocytes, we elucidated that mitogen-activated protein kinase 7 (MAPK7, also known as ERK5)-mediated CCAAT/enhancer-binding protein beta (CEBPβ) transcriptionally represses mir128-3p under hypoxia. Therapeutically, functional studies demonstrated gene therapy-delivered cardiac-specific MAPK7 restoration or overexpression of CEBPβ impeded cardiac injury after MI, at least partly due to normalization of mir128-3p. Furthermore, inhibition of mir128-3p preserved Irs1 and ameliorated cardiac dysfunction post-MI. In conclusion, we reveal that targeting mir128-3p mitigates myocardial insulin resistance, thereafter slowing down the progression of heart failure post-ischemia.